Abbott Launches VOYAGER CE Trial of Encantor Valve

The pre-market study will enroll up to 300 patients with severe aortic stenosis across Europe and Australia.

Updated on Nov. 20, 2026 in Heart Disease

Close view of a crimped metal valve frame on a balloon catheter resting on a steel instrument tray under cool surgical light.
Abbott has started the VOYAGER CE trial of its Encantor transcatheter aortic valve, enrolling up to 300 severe aortic stenosis patients in Europe and Australia. AI Illustration. Upload story photo >

Abbott has initiated the VOYAGER CE clinical trial of its Encantor transcatheter aortic valve implantation (TAVI) system, with first patient enrollment occurring at Macquarie University in Sydney, Australia. The prospective, single-arm, pre-market study will enroll up to 300 patients with symptomatic severe aortic stenosis in Europe and Australia.

Why it matters

Aortic stenosis narrows the aortic valve as calcium builds up, and the study is intended to form the basis for seeking regulatory approval of the device in Europe and Australia. Successful completion of the trial and receipt of approvals would expand Abbott's structural heart portfolio.

The VOYAGER CE study is a single-arm, pre-market study enrolling up to 300 patients, and early feasibility six-month data will be presented at PCR London Valves on Nov. 22, 2026. Trial outcomes and regulatory decisions remain unresolved at this stage.

The players

Abbott

Abbott is a global healthcare company with a structural heart portfolio that includes transcatheter valve technologies.

Stephen Worthley, M.B.B.S, Ph.D.

Stephen Worthley is a cardiologist who led first patient enrollment in the VOYAGER CE study at Macquarie University in Sydney.

Didier Tchétché, M.D.

Didier Tchétché is an interventional cardiologist at Clinique Pasteur in Toulouse, France, serving as co-principal investigator of the study.

The details

The Encantor system is a balloon-expandable TAVI device that crimps the new valve onto a deflated surgical balloon, which is guided through a catheter in an artery in the groin to the heart. Didier Tchétché, M.D., is co-principal investigator of the study, and Stephen Worthley, M.B.B.S, Ph.D., led first enrollment at Macquarie University.

Timeline

  1. Nov. 22, 2026: Early feasibility six-month data presented at PCR London Valves.

  2. Nov. 22-24, 2026: PCR London Valves 2026 conference held in London.

Health Landscape

Transcatheter aortic valve implantation has offered a catheter-based route to valve replacement that avoids open-heart surgery for patients with severe aortic stenosis. The VOYAGER CE study extends this approach by evaluating Abbott's balloon-expandable Encantor system in a new prospective cohort of up to 300 patients.

For patients with symptomatic severe aortic stenosis in Europe and Australia, the VOYAGER CE study may eventually lead to a new catheter-based valve replacement option if it receives regulatory approval. The trial is still enrolling, so the device is not yet available for routine clinical use.

The takeaway

Patients with severe aortic stenosis should discuss all available valve replacement options with their cardiology team, as new devices remain under clinical evaluation before approval.

What happens next

Early feasibility six-month data from the study will be presented at PCR London Valves on Nov. 22, 2026.

Further reading

For background on the condition this device treats, explore our Heart Disease coverage.